683 Capital Management LLC Acquires Shares of 1,050,000 Shattuck Labs, Inc. (NASDAQ:STTK)

683 Capital Management LLC bought a new stake in Shattuck Labs, Inc. (NASDAQ:STTK - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,050,000 shares of the company's stock, valued at approximately $1,270,000. 683 Capital Management LLC owned approximately 2.20% of Shattuck Labs at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Zacks Investment Management bought a new stake in Shattuck Labs during the fourth quarter worth about $25,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs during the 4th quarter worth approximately $30,000. JPMorgan Chase & Co. raised its stake in shares of Shattuck Labs by 63.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company's stock worth $96,000 after purchasing an additional 10,667 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at approximately $45,000. Finally, Barclays PLC grew its stake in shares of Shattuck Labs by 299.5% in the third quarter. Barclays PLC now owns 54,311 shares of the company's stock valued at $189,000 after buying an additional 40,717 shares in the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Trading Down 7.8 %

STTK stock traded down $0.08 during mid-day trading on Friday, hitting $1.00. 115,468 shares of the company were exchanged, compared to its average volume of 379,533. Shattuck Labs, Inc. has a 1-year low of $0.69 and a 1-year high of $11.76. The business has a 50 day simple moving average of $1.04 and a 200-day simple moving average of $1.15. The stock has a market capitalization of $47.69 million, a PE ratio of -0.65 and a beta of 1.76.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.02. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. Equities research analysts expect that Shattuck Labs, Inc. will post -1.48 earnings per share for the current year.

Wall Street Analyst Weigh In

STTK has been the subject of a number of recent analyst reports. Leerink Partnrs upgraded shares of Shattuck Labs to a "strong-buy" rating in a research note on Monday, March 17th. Needham & Company LLC reissued a "hold" rating on shares of Shattuck Labs in a research report on Thursday, March 27th. HC Wainwright reaffirmed a "neutral" rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Finally, Leerink Partners started coverage on Shattuck Labs in a report on Monday, March 17th. They set an "outperform" rating and a $4.00 target price on the stock. Four research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.